Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P13693
UPID:
TCTP_HUMAN
Alternative names:
Fortilin; Histamine-releasing factor; p23
Alternative UPACC:
P13693; B2R7E5; Q6YLS2; Q7Z4J4; Q8TBK7; Q96EE2; Q9UC70
Background:
The Translationally-controlled tumor protein, also known as Fortilin, Histamine-releasing factor, or p23, plays a crucial role in cellular processes, including calcium binding and microtubule stabilization. Its ability to interact with and destabilize the TSC22D1 protein positions it as a negative regulator of TSC22D1-mediated apoptosis, highlighting its significance in cellular survival and proliferation mechanisms.
Therapeutic significance:
Understanding the role of Translationally-controlled tumor protein could open doors to potential therapeutic strategies. Its involvement in key cellular processes underscores its potential as a target for therapeutic intervention in diseases where these processes are dysregulated.